Rofael Hany Z
Department of Pharmacology and Physiology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07101, USA.
Toxicol Lett. 2004 Sep 25;152(3):213-22. doi: 10.1016/j.toxlet.2004.04.035.
Cocaine (COC) produces hepatotoxicity by a mechanism, which remains undefined, but has been linked to its oxidative metabolism. Ketamine (KET) is also a potentially hepatotoxic agent. The abuse of KET with COC is currently popular among young abusers therefore; this study was conducted to investigate the possible potentiation of COC-mediated hepatotoxicity (CMH) by KET. Male Sprague Dawley (SD) rats were administered oral KET hydrochloride for three consecutive days at a dose of 100 mg/kg with and without a single dose of COC (5 mg/kg, i.v.) administered 18 h after the last KET dose. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured as markers of liver injury. Liver reduced glutathione (GSH) levels were determined as well as the activities of glutathione peroxidase (GPx) and catalase (CAT). In addition, the activity of liver glutathione reductase (GRx) was measured. The results demonstrate that KET pretreatment potentiated the hepatotoxicity of COC. Serum ALT and AST were significantly elevated with the combined KET and COC treatment versus all other treatments. While COC alone resulted in focal inflammatory cell infiltration, COC administration after KET pretreatment produced sub-massive hepatic necrosis. Hepatic GSH content was significantly reduced in KET-pretreated COC group compared to the other treatment groups, rendering the liver more susceptible to oxidative stress. Moreover, there was a significant decrease in the activities of hepatic GPx and CAT, particularly with the KET-pretreated COC group. In addition, norcocaine (NC) was only detected in the plasma of rats received COC after KET pretreatment. In conclusion, this study demonstrates that KET pretreatment potentiates the hepatotoxicity of COC as revealed by an array of biochemical and morphological markers most probably due to increase in COC oxidative metabolism.
可卡因(COC)通过一种机制产生肝毒性,该机制尚不清楚,但与它的氧化代谢有关。氯胺酮(KET)也是一种潜在的肝毒性药物。因此,KET与COC共同滥用目前在年轻滥用者中很普遍。本研究旨在调查KET是否可能增强COC介导的肝毒性(CMH)。雄性Sprague Dawley(SD)大鼠连续三天口服盐酸KET,剂量为100mg/kg,在最后一次KET给药18小时后,分别给予和不给予单剂量的COC(5mg/kg,静脉注射)。测定血清丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)作为肝损伤的标志物。测定肝脏还原型谷胱甘肽(GSH)水平以及谷胱甘肽过氧化物酶(GPx)和过氧化氢酶(CAT)的活性。此外,还测定了肝脏谷胱甘肽还原酶(GRx)的活性。结果表明,KET预处理增强了COC的肝毒性。与所有其他处理相比,KET和COC联合处理使血清ALT和AST显著升高。单独使用COC导致局灶性炎性细胞浸润,而KET预处理后给予COC则导致亚大块肝坏死。与其他处理组相比,KET预处理的COC组肝脏GSH含量显著降低,使肝脏更容易受到氧化应激的影响。此外,肝脏GPx和CAT的活性显著降低,尤其是KET预处理的COC组。此外,仅在KET预处理后接受COC的大鼠血浆中检测到去甲可卡因(NC)。总之,本研究表明,KET预处理增强了COC的肝毒性,一系列生化和形态学标志物显示了这一点,这很可能是由于COC氧化代谢增加所致。